[SCHEDULE 13G/A] CytomX Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

The Vanguard Group filed Amendment No. 10 to Schedule 13G on 29 Jul 2025, disclosing its passive ownership of Apple Inc. (AAPL) as of 30 Jun 2025.

Vanguard beneficially owns 1,415,826,462 Apple common shares, representing 9.47 % of the outstanding class. It reports 0 shares with sole voting power and 19,800,347 shares with shared voting power, while holding sole dispositive power over 1,343,278,627 shares and shared dispositive power over 72,547,835 shares.

The firm qualifies as an investment adviser under Rule 13d-1(b)(1)(ii)(E) and certifies the holdings were acquired in the ordinary course of business, with no intent to influence Apple’s control. No additional material transactions or strategic intentions are noted.

Positive

• Vanguard reports ownership of 1.42 B Apple shares (9.47 % of the company), confirming strong institutional presence.

Negative

• None.

Insights

Securities Analyst

TL;DR: Vanguard’s 9.47 % stake is sizeable but passive; disclosure is largely routine, implying neutral market impact.

The filing confirms Vanguard as Apple’s largest passive holder with 1.42 B shares. Voting power remains minimal (only 19.8 M shared votes), underscoring a non-activist posture. Staying below the 10 % threshold avoids additional regulatory obligations and insider scrutiny. Because no new strategic intentions or transactions accompany the stake, the disclosure is informational rather than catalytic for AAPL’s valuation. Institutional ownership at this level is consistent with index-tracking mandates and does not alter governance dynamics in a material way.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

CytomX Therapeutics Inc

(Name of Issuer)

Common Stock

(Title of Class of Securities)

23284F105

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23284F105

1

Names of Reporting Persons

The Vanguard Group

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

PENNSYLVANIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 9,311,128.00
8	Shared Dispositive Power 68,666.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

9,379,794.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.95 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CytomX Therapeutics Inc
(b)	Address of issuer's principal executive offices: 151 Oyster Point Blvd, Suite 400, South San Francisco, CA, 94080
Item 2.
(a)	Name of person filing: The Vanguard Group
(b)	Address or principal business office or, if none, residence: 100 Vanguard Blvd., Malvern, PA 19355
(c)	Citizenship: PA
(d)	Title of class of securities: Common Stock
(e)	CUSIP No.: 23284F105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 9379794
(b)	Percent of class: 5.95 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 0
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 9311128
	(iv) Shared power to dispose or to direct the disposition of: 68666
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein. No one other person's interest in the securities reported herein is more than 5%.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

The Vanguard Group

Signature:	Ashley Grim
Name/Title:	Head of Global Fund Administration
Date:	07/29/2025

FAQ

How many Apple (AAPL) shares does Vanguard own according to the July 2025 Schedule 13G?

Vanguard reports 1,415,826,462 shares beneficially owned.

What percentage of Apple’s outstanding shares is held by Vanguard?

The stake represents 9.47 % of the common stock class.

Does Vanguard have voting control over its Apple shares?

It lists 0 sole voting power and 19,800,347 shares with shared voting power.

Under which SEC rule was this Schedule 13G filed?

The filing is made pursuant to Rule 13d-1(b) as an investment adviser.

What purpose does Vanguard state for holding Apple shares?

The shares are held in the ordinary course of business with no intent to influence control of Apple.